Jagodzinska, Barbara, Ph.D.
  • Senior Medicinal Chemist, Drug Discovery Laboratory, Department of Neurology, David Geffen School of Medicine at UCLA

Jagodzinska, Barbara, Ph.D.


Drug Discovery Laboratory
UCLA Department of Neurology
710 Westwood Plaza, Reed Building - Room 3256
Los Angeles, CA 90095-1769
Tel: (310) 206-4708
Fax: (310) 825-6956
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.



Medicinal Chemistry, Drug Discovery, Analoging by searching and pharmacophore building based on SAR, Alzheimer's disease.



Dr. Jagodzinska is a medicinal chemist, member of a Drug Discovery & Translational Laboratory at the Department of Neurology at UCLA with many years of drug discovery experience in the pharmaceutical industry (Elan Pharmaceuticals, Novartis and Kelsius Inc.). She is a member of the Alzheimer’s Disease Program in the Mary S. Easton Center for Alzheimer's Disease that is under the direction of Professor Dale E. Bredesen, M.D., Visiting Professor of Neurology, Department of Neurology, UCLA. For the last several years Dr. Jagodzinska consulted the Alzheimer's Drug Development Network (ADDN), a network that was originally co-founded by Drs. John and Bredesen at the Buck Institute for Research on Aging in Novato. At ADDN she focused on drug discovery with novel targets in neurodegenerative diseases and AD through analoging and small molecule optimization for potency and bioavailability. In collaboration with the Dominican University of California she established a Medicinal Chemistry Laboratory for preparation and characterization of analogs.
During her tenure at Elan Pharmaceuticals, Dr. Jagodzinska was part of the γ-secretase and BACE inhibitor program teams. Systematically synthesized a family of inhibitors and identified a target specific nanomolar lead candidates as effective inhibitors of APP processing. She acted as a liaison between Chemistry and Pharmacology during optimization phase of the AD project during collaboration between Elan and Pharmacia, later Pfizer.
Dr. Jagodzinska is an author of over 20 publications and issued or pending patents on compounds and analogs for CNS related targets.



  • Ph.D. Natural Product Chemistry, University of Warsaw, Poland.
  • Fellow, Dr. Carl Djerassi Laboratory, Stanford.


Publications (selected peer-reviewed publications)

  • Sealy JM, Truong AP, Tso L, Probst GD, Aquino J, Hom RK, Jagodzinska BM, Dressen D, Wone DWG, Brogley L, John V, Tung JS, Pleiss MA, Tucker JA, Konradi AW, Dappen MS, Toth G, Pan H, Ruslim L, Miller J, Bova MP, Sinha S, Quinn KP, Sauer JM. Design and synthesis of cell potent BACE-1 inhibitors: Structure-activity relationship of P1' substituents. Bioorganic & Medicinal Chemistry Letters 2009;19(22):6386-6391. PMID: 19811916
  • Probst GD, Bowers S, Sealy JM, Stupi B, Dressen D, Jagodzinska BM, Aquino J, Gailunas A, Truong AP, Tso L, Xu YZ, Hom RK, John V, Tung JS, Pleiss MA, Tucker JA, Konradi AW, Sham HL, Jagodzinski J, Toth G, Brecht E, Yao N, Pan H, Lin M, Artis DR, Ruslim L, Bova MP, Sinha S, Yednock TA, Gauby S, Zmolek W, Quinn KP, Sauer JM. Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: Structure-activity relationship of the aryl region. Bioorganic & Medicinal Chemistry Letters 2010;20(20):6034-6039. PMID: 20822903
  • Descamps O, Spilman P, Zhang Q, Libeu CP, Poksay K, Gorostiza O, Campagna J, Jagodzinska B, Bredesen DE, John V. AβPP-Selective BACE Inhibitors (ASBI): Novel Class of Therapeutic Agents for Alzheimer's Disease. Journal of Alzheimer's Disease 2013;37(2):343-355. PMID: 23948888; PMCID: PMC3971881
  • Alam MP, Jagodzinska B, Campagna J, Spilman P, John V. C-O bond formation in a microfluidic reactor: high yield SNAr substitution of heteroaryl chlorides. Tetrahedron Letter 2016;57(19):2059-2062. doi:10.1016/j.tetlet.2016.03.095


Health Professionals